WO2006115660A2 - Transdermal systems for the delivery of therapeutic agents including granisetron using iontophoresis - Google Patents
Transdermal systems for the delivery of therapeutic agents including granisetron using iontophoresis Download PDFInfo
- Publication number
- WO2006115660A2 WO2006115660A2 PCT/US2006/010781 US2006010781W WO2006115660A2 WO 2006115660 A2 WO2006115660 A2 WO 2006115660A2 US 2006010781 W US2006010781 W US 2006010781W WO 2006115660 A2 WO2006115660 A2 WO 2006115660A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- granisetron
- dose
- donor
- iontophoresis
- reservoir
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/20—Applying electric currents by contact electrodes continuous direct currents
- A61N1/30—Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/0404—Electrodes for external use
- A61N1/0408—Use-related aspects
- A61N1/0428—Specially adapted for iontophoresis, e.g. AC, DC or including drug reservoirs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M2037/0007—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin having means for enhancing the permeation of substances through the epidermis, e.g. using suction or depression, electric or magnetic fields, sound waves or chemical agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/0404—Electrodes for external use
- A61N1/0408—Use-related aspects
- A61N1/0428—Specially adapted for iontophoresis, e.g. AC, DC or including drug reservoirs
- A61N1/0432—Anode and cathode
- A61N1/044—Shape of the electrode
Definitions
- the present invention is related generally to transdermal delivery of therapeutic agents by the use of an applied electro motive force (emf) , commonly known as iontophoresis. More specifically, this invention relates to the transdermal delivery of agents such as the anti- emesis agent granisetron.
- emf electro motive force
- iontophoresis was described by LeDuc in 1908 and has since found commercial use in the delivery of ionically charged therapeutic agent molecules such as pilocarpine, lidocaine and dexamethasone.
- ions bearing a positive charge are driven across the skin at the site of an electrolytic electrical system anode while ions bearing a negative charge are driven across the skin at the site of an electrolytic system cathode.
- iontophoretic devices have been typically constructed of two electrodes attached by adhesive materials to a patient, each connected by a wire to a remote power supply, generally a microprocessor-controlled electrical instrument. More recently, self-contained wearable iontophoretic systems have been developed. These systems are advantageous in that they do not have external wires and are much smaller in size. Examples of such systems can be found in a variety of U.S. patents, examples of which include U.S. Patent 4,927,408; 5,358,483;
- iontophoretic devices can incorporate an ability to modify delivery rates with simple adjustments to the magnitude of current flow. This ability can be used to create a wearable system, wherein patients can self-adjust medication delivery in accordance to individual needs.
- Patents 6,171,294; 6,216,033; 6,425,892; and 6,745,071 describe iontophoretic devices where patients can self-adjust pain management dosing of fentanyl or sufentanyl using either on-demand bolus dosing or changes in continuous delivery rate.
- the present invention relates to an improved application of iontophoresis useful for the treatment of emesis.
- Emesis in the form of nausea and vomiting, commonly occurs following chemotherapy, post-operatively following treatment with anesthetic agents, or after exposure to biologic agents and/or radiation, possibly in a military setting.
- oral dosage forms are convenient, but are unreliable because in the case of emesis, patients may be unable to keep the medication ingested.
- Granisetron is a selective antagonist of 5- hydroxytryptamine (5-HT3) receptors, and commercially available in oral or injectable dosage forms. It is known to be an effective agent for the management of emesis, as both a primary dose and as a "rescue dose" medication.
- rescue dose is defined as an additional dose necessary to treat breakthrough or recurring symptoms.
- rescue dose is defined as an additional dose necessary to treat breakthrough or recurring symptoms.
- Dose finding study of granisetron in patients receiving high-dose cisplatin chemotherapy by A. Riviere in Br. J. Cancer, 69, 967-971 (1994), which provides an informative summary of clinical effectiveness of granisetron administered both as primary and rescue dosing medication.
- a disadvantage of injectable administration forms lies in the invasive nature of injections, which can be painful, require clinical skill, can lead to infection, and are therefore are not suitable to self administration in a field or home setting.
- transdermal administration process includes delivery systems for transdermal administration by: passive patches, heated passive patches, passive patches applied onto RF treated skin, and spray-on- skin systems where the total amount applied is fixed and delivery is improved by co-formulated permeation enhancers.
- delivery systems for transdermal administration by: passive patches, heated passive patches, passive patches applied onto RF treated skin, and spray-on- skin systems where the total amount applied is fixed and delivery is improved by co-formulated permeation enhancers.
- One advantage of transdermal systems is an ability to provide a sustained release of medication over time, which may serve to provide a longer duration of action.
- a significant limitation and disadvantage of passive transdermal administration is a slow onset of sufficient action to provide relief. It is not uncommon for a passive transdermal patch to take several hours (3 or more) before a therapeutic dosage is achieved. With passive transdermal delivery, the skin can act as a depot, and release to the bloodstream will not occur until that skin depot area is saturated.
- This slow onset of action acts as a clinical limitation in two respects: 1) it cannot replace an existing oral or injectable form because it is a necessity to apply a patch several hours prior to a chemotherapy or operative procedure, and 2) a slow acting transdermal patch cannot reasonably serve as a rescue medication form, where a patient will prefer, for obvious reasons, a faster acting treatment.
- This second limitation is significant, in that it has been shown that, in many cases of highly emetogenic therapies, such as high dose chemotherapy, a significant percentage of patients will not be adequately served by a first, primary dosage form alone. A more rapid onset of action can be achieved transdermally by using a system that includes iontophoresis. Granisetron in its hydrochloride salt form, is positively charged and can be delivered rapidly from a positively charged anode pad.
- Scientific Abstract 1 Evaluation of iontophoretic permeation kinetics of granisetron through skin by subcutaneous microdialysis, presented at the 2003 AAPS meeting October, 2003;
- Scientific Abstract 2 IVIVC of Iontophoretic Delivery of granisetron by subcutaneous microdialysis, presented at the 2004 AAPS meeting October, 2004, have demonstrated that with iontophoresis, a therapeutic dosage can be achieved (in a hairless rat animal model) within approximately two-hours.
- the present invention provides a transdermal iontophoresis device and method that has the ability to administer a bolus dosage of a therapeutic agent, particularly a therapeutic granisetron bolus dosage rapidly using a single-use, disposable transdermal patch.
- the patch of the invention provides an onset of a therapeutic level of action in generally less than one hour.
- at least one embodiment of the patch device enables a patient to rapidly self-administer at least a second or rescue dose after the initial primary dose.
- a disposable skin-worn patch device for the transdermal delivery of a plurality of doses of a charged therapeutic substance such as granisetron by iontophoresis.
- the device includes a reservoir from which the therapeutic agent is delivered into the body (donor reservoir) containing an amount of the substance to be delivered transdermally by iontophoresis and one or more donor electrodes, a counter reservoir containing a counter electrode which serves to complete the electrical circuit through the body, a source of electric power connected in a circuit between the donor reservoir and the counter reservoir and a user-operable control system for controlling current flow in the circuit to enable a plurality of successive doses of therapeutic substance to be administered from the donor reservoir.
- the multiple doses may be controlled by switching and selectively connecting each one of a plurality of donor electrodes designed to be oxidized or reduced in the iontophoresis circuit operation.
- microprocessor or other electronic or electrical control circuits can be used to regulate the rate of current flow, and therefore the rate of medication delivery.
- a control circuit is implemented to create a device which can provide bolus and/or alternative waveform dosing from a single donor electrode configuration.
- a first dose may be provided automatically by the application of the patch to the skin of a patient by a pre- determined switching device in the circuit.
- the patch also can be employed to supply a sustained, lower- level delivery rate of granisetron following an initial bolus dose.
- Such as system is illustrated and described, for example, in U.S. Patent 6,421,051 assigned to the same assignee as the present application and which is deemed incorporated herein by reference for any purpose.
- a disposable skin-worn patch incorporates an activation system to automatically administer granisetron after a sensor triggers the system based on an alarm signal.
- That control system is designed to respond to an externally generated signal, such as a radio frequency signal which may be given to a plurality of such devices as might be worn by soldiers in a military setting.
- a switch device may be provided in the circuit to prevent accidental activation from occurring in stored patches.
- one preferred therapeutic substance to be delivered is granisetron.
- the granisetron may preferably be contained in a hydrogel formulation and preferably as a charged species which can only successfully be delivered in a therapeutic dose utilizing an active iontophoresis technique.
- granisetron and other therapeutically active species contained in an ionic or charged form, for iontophoresis deliveries migrate transdermally only slightly using passive application systems. Such an approach would not deliver a therapeutically effective level of material.
- Hydrogels based on polyvinylalcohol, hydroxypropylmethylcellulose (HPMC) , and polyethylene oxide are examples of hydrogels that can co-formulated with the granisetron.
- a therapeutic dose of granisetron is generally accepted to be between about 300 ⁇ g and 1000 ⁇ g.
- Patches in accordance with the present invention have the capacity ' to administer or deliver a bolus dosage between about 300 ⁇ g and 1000 ⁇ g, in less than about 1 hour.
- an iontophoretic charge dosage between 20 and 60 mAmin can be used to successfully deliver this amount, so that current in the range of 0.3 and 1.0 mA would be required for a one-hour delivery period.
- the delivery pad contact area needs to be sized with consideration given to this as a desired current density range.
- the total granisetron content supplied in the donor reservoir or pad should exceed the desired total quantity to be delivered by a significant amount. Generally, this has been found to be a factor of two or even more.
- the desired total dosage to be delivered for example, is 2 milligrams (2mg)
- at least 4mg should be provided in the donor reservoir or pad.
- significant loss of delivery efficiency is seen in a second or rescue dose if the total content of granisetron in the patch is less than twice the total amount of granisetron desired to be delivered.
- Figure 1 is a schematic representation of an embodiment of a transdermal patch in accordance with the invention capable of delivering a plurality of doses of a therapeutic agent ;
- FIG. 2 is a schematic representation of an alternate embodiment of a transdermal patch in accordance with the invention selectively designed to be activated by an external signal;
- Figure 3 is a schematic representation of another embodiment of the invention capable of delivering a plurality of doses of a therapeutic agent utilizing a single donor electrode;
- Figure 4 is a schematic representation of an embodiment similar to that in Figure 2 including an element to preclude untimely activation.
- Figure 1 represents an iontophoretic patch device that automatically releases a dosage of granisetron or other therapeutic agent upon application of the device to the skin. That device is additionally capable of releasing a second dosage after a patient activates a switching device.
- FIG. 1 illustrates an iontophoretic self-powered skin-applied adhesive patch device generally at 10.
- the patch includes a cathode chamber or counter reservoir 12 containing a cathode or counter electrode 14 and an anode chamber or donor reservoir 16 containing a pair of anodes 18 and 20 spaced and electrically isolated from each other, but electrically connected to respective conductors 22 and 24 and to the material in the reservoir 16.
- a two-position switch element is shown at 26 and a pair of power sources, which may be conventional button-type batteries are shown connected in series at 28 and 30. Additional interconnecting conductor elements are shown at 32, 34 and 36.
- the switch 26 either anode 18 or 20 can be selectively connected or patched into a circuit which is completed by the application of the patch 10 to the skin of a patient, as is well known.
- the charge capacity and so the dosage associated with either anode 18 or 20 can further be adjusted to any desired amount as by adjusting the content of oxidizable species at each anode such that depletion of the oxidizable species or isolation of the connection will produce an open circuit condition with that anode connected. Techniques for this are illustrated and described in U.S. Patent 6,653,014 assigned to the same assignee as the present application and which is hereby incorporated by reference herein for any purpose .
- the circuit can include elements to limit or control current flow in a known manner to produce a longer-lasting lower dosage at any switch position. For example, it may be desired to administer a low steady dose of granisetron of perhaps about 40 ⁇ g/hr over a long period of time after an initial bolus or first primary dose has been administered. Also, additional or other types of DC power sources and controls including programmed controls optionally such as shown in Figure 3, for example, can be used.
- the iontophoresis patch device of Figure 1 When the iontophoresis patch device of Figure 1 is adhesively applied to the skin of a patient, this will complete a first circuit including a selectively included anode 18, 20 and the patch will immediately activate and begin to deliver a dosage of granisetron or other therapeutic agent contained in the anode or donor reservoir commensurate with the amount of oxidizable species available to the circuit at the then connected anode.
- This will preferably be preset by the position of the switch 26 set at the point of manufacture so that a known initial bolus of the granisetron as an initial therapeutic dosage can be delivered rapidly as soon as the device is applied to the skin of a user.
- the alternate embodiment of Figure 2 includes a similar skin-applied, self-powered adhesive patch 40 which includes a cathode chamber or counter reservoir 42 with cathode or counter electrode 44, an anode chamber or donor reservoir 46 provided with a single anode or donor electrode 48.
- a normally open switch or other activation element or device 50 connected with an associated sensor 52 for receiving external activation signals, is provided in the circuit between anode 48 and a pair of series-connected power sources 54 and 56. Connecting conductive elements are shown at 58 , 60 , 62 and 64 .
- This embodiment is designed to be worn by one potentially in need of receiving a dose of the therapeutic material of the patch. Activation of the patch and delivery of the medication, however, is controlled by an externally generated signal being received by sensor 52 which, in turn, triggers the element 50 to close a switch or otherwise function to complete the circuit.
- the embodiment 40 is shown with a single anode and so is designed to deliver a single dose to the wearer.
- the sensing device 52 may be designed to receive any of many types of signals including radio frequency, audio, infrared, etc., and a single signal may activate the patches of many wearers as might occur among troops commonly engaged in a military setting.
- This embodiment provides a means for automated iontophoretic transdermal granisetron administration in a military field setting, as may be required for example, with an unexpected exposure of soldiers to radiation and/or chemical and biological agents.
- Figure 4 depicts a sensor-activated embodiment 40a, similar to that shown in Figure 2 that is provided with a user activated element to provide protection against unwanted activation of the patch (such as in storage) .
- the embodiment of Figure 4 is provided with a manually-operated switch as at 70 which is designed to be closed by the user prior to sensor-controlled activation. In an open position, switch 70 interrupts the power on conductor 60 thereby disconnecting the power source 56. The closing of the switch 70 also actives the sensor 52 which is otherwise in an off mode.
- This embodiment is shown with a single power source 56 but as was the case in the embodiment of Figure 2, additional power sources, or other controls as in Figure 3, of course, may be used.
- FIG. 3 A further embodiment 10a is shown in Figure 3 in which an electronic control circuit or element 37 is connected by a conductor 38 to switch 26 and by a conductor 39 to power source 28.
- the electronic control circuit element 37 may include a microprocessor or a microprocessor-operated control which may be a timing controller such as are well known and which may operate in conjunction with a single donor electrode 20a to deliver a plurality of doses from the patch as controlled by the element 37 and switch 26.
- This is an alternative operating scheme to that of sequential electrode depletion shown in Figure 1.
- the control system may be used to provide a sustained or steady low-level delivery of therapeutic agent. In the case of granisetron, this may be about 30-50 ⁇ g/hr and preferably about 40 ⁇ g/hr, for example .
- the examples of the detailed description show the administration of a therapeutic agent in which the donor reservoir is the anode chamber.
- an oppositely charged material might be administered using the cathode chamber as the donor reservoir and the anode chamber as the counter reservoir.
- Other variations in configuration and control are also contemplated. These may include circuit components to control delivery power over time or the like.
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2608471A CA2608471C (en) | 2005-04-22 | 2006-03-24 | Transdermal systems for the delivery of therapeutic agents including granisetron using iontophoresis |
ES06748647.2T ES2529454T3 (en) | 2005-04-22 | 2006-03-24 | Transdermal systems for administration by iontophoresis therapeutic agents that include granisetron |
AU2006240432A AU2006240432B2 (en) | 2005-04-22 | 2006-03-24 | Transdermal systems for the delivery of therapeutic agents including granisetron using iontophoresis |
CN2006800217869A CN101203266B (en) | 2005-04-22 | 2006-03-24 | Transdermal systems for the delivery of therapeutic agents including granisetron using iontophoresis |
EP06748647.2A EP1877134B1 (en) | 2005-04-22 | 2006-03-24 | Transdermal systems for the delivery of therapeutic agents including granisetron using iontophoresis |
HK08113266.2A HK1120451A1 (en) | 2005-04-22 | 2008-12-05 | Transdermal systems for the delivery of therapeutic agents including granisetron using iontophoresis |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/112,196 | 2005-04-22 | ||
US11/112,196 US7856263B2 (en) | 2005-04-22 | 2005-04-22 | Transdermal systems for the delivery of therapeutic agents including granisetron using iontophoresis |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006115660A2 true WO2006115660A2 (en) | 2006-11-02 |
WO2006115660A3 WO2006115660A3 (en) | 2007-11-15 |
Family
ID=37215186
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/010781 WO2006115660A2 (en) | 2005-04-22 | 2006-03-24 | Transdermal systems for the delivery of therapeutic agents including granisetron using iontophoresis |
Country Status (9)
Country | Link |
---|---|
US (3) | US7856263B2 (en) |
EP (1) | EP1877134B1 (en) |
KR (1) | KR100994631B1 (en) |
CN (1) | CN101203266B (en) |
AU (1) | AU2006240432B2 (en) |
CA (1) | CA2608471C (en) |
ES (1) | ES2529454T3 (en) |
HK (1) | HK1120451A1 (en) |
WO (1) | WO2006115660A2 (en) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0210397D0 (en) | 2002-05-07 | 2002-06-12 | Ferring Bv | Pharmaceutical formulations |
US8722235B2 (en) | 2004-04-21 | 2014-05-13 | Blue Spark Technologies, Inc. | Thin printable flexible electrochemical cell and method of making the same |
US8029927B2 (en) | 2005-03-22 | 2011-10-04 | Blue Spark Technologies, Inc. | Thin printable electrochemical cell utilizing a “picture frame” and methods of making the same |
US8722233B2 (en) | 2005-05-06 | 2014-05-13 | Blue Spark Technologies, Inc. | RFID antenna-battery assembly and the method to make the same |
MX2008012922A (en) * | 2006-04-13 | 2008-12-17 | Nupathe Inc | Transdermal methods and systems for the delivery of anti-migraine compounds. |
EP2176814A4 (en) | 2007-07-18 | 2012-06-13 | Blue Spark Technologies Inc | Integrated electronic device and methods of making the same |
KR20140143461A (en) | 2007-08-06 | 2014-12-16 | 알레간 인코포레이티드 | Methods and devices for desmopressin drug delivery |
US8574754B2 (en) | 2007-12-19 | 2013-11-05 | Blue Spark Technologies, Inc. | High current thin electrochemical cell and methods of making the same |
JP5767103B2 (en) | 2008-05-21 | 2015-08-19 | フエリング・インターナシヨナル・センター・エス・アー | Orally disintegrating desmopressin to increase the initial period of sleep unimpeded by nocturia |
US20100286045A1 (en) | 2008-05-21 | 2010-11-11 | Bjarke Mirner Klein | Methods comprising desmopressin |
US8155737B2 (en) * | 2008-06-19 | 2012-04-10 | Nupathe, Inc. | Pharmacokinetics of iontophoretic sumatriptan administration |
US8366600B2 (en) * | 2008-06-19 | 2013-02-05 | Nupathe Inc. | Polyamine enhanced formulations for triptan compound iontophoresis |
WO2011019732A1 (en) * | 2009-08-10 | 2011-02-17 | Nupathe, Inc. | Methods for iontophoretically treating nausea and migraine |
US20110087153A1 (en) * | 2009-10-13 | 2011-04-14 | Angelov Angel S | Transdermal Methods And Systems For The Delivery Of Rizatriptan |
WO2013044224A2 (en) | 2011-09-22 | 2013-03-28 | Blue Spark Technologies, Inc. | Cell attachment method |
WO2013177202A1 (en) | 2012-05-21 | 2013-11-28 | Blue Spark Technologies, Inc. | Multi-cell battery |
US9782082B2 (en) | 2012-11-01 | 2017-10-10 | Blue Spark Technologies, Inc. | Body temperature logging patch |
US9444078B2 (en) | 2012-11-27 | 2016-09-13 | Blue Spark Technologies, Inc. | Battery cell construction |
US10675254B2 (en) * | 2013-10-11 | 2020-06-09 | Teikoku Seiyaku Co., Ltd. | Sphingosine-1-phosphate receptor agonist iontophoretic devices and methods of using the same |
US9693689B2 (en) | 2014-12-31 | 2017-07-04 | Blue Spark Technologies, Inc. | Body temperature logging patch |
US10849501B2 (en) | 2017-08-09 | 2020-12-01 | Blue Spark Technologies, Inc. | Body temperature logging patch |
Family Cites Families (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US536221A (en) * | 1895-03-26 | Electric switch | ||
US4856188A (en) * | 1984-10-12 | 1989-08-15 | Drug Delivery Systems Inc. | Method for making disposable and/or replenishable transdermal drug applicators |
US5651768A (en) * | 1983-08-18 | 1997-07-29 | Drug Delivery Systems, Inc. | Transdermal drug applicator and electrodes therefor |
US4708716A (en) * | 1983-08-18 | 1987-11-24 | Drug Delivery Systems Inc. | Transdermal drug applicator |
US5605536A (en) * | 1983-08-18 | 1997-02-25 | Drug Delivery Systems Inc. | Transdermal drug applicator and electrodes therefor |
CA1262564A (en) * | 1983-09-01 | 1989-10-31 | Minoru Sasaki | Iontophoresis device |
US4927408A (en) * | 1988-10-03 | 1990-05-22 | Alza Corporation | Electrotransport transdermal system |
US5496266A (en) * | 1990-04-30 | 1996-03-05 | Alza Corporation | Device and method of iontophoretic drug delivery |
US5088977A (en) * | 1988-12-21 | 1992-02-18 | Drug Delivery Systems Inc. | Electrical transdermal drug applicator with counteractor and method of drug delivery |
US5125894A (en) * | 1990-03-30 | 1992-06-30 | Alza Corporation | Method and apparatus for controlled environment electrotransport |
US6004309A (en) * | 1990-03-30 | 1999-12-21 | Alza Corporation | Method and apparatus for controlled environment electrotransport |
US5207752A (en) * | 1990-03-30 | 1993-05-04 | Alza Corporation | Iontophoretic drug delivery system with two-stage delivery profile |
US5084006A (en) * | 1990-03-30 | 1992-01-28 | Alza Corporation | Iontopheretic delivery device |
US5147297A (en) * | 1990-05-07 | 1992-09-15 | Alza Corporation | Iontophoretic delivery device |
DE4014913C2 (en) * | 1990-05-10 | 1996-05-15 | Lohmann Therapie Syst Lts | Miniaturized transdermal therapeutic system for iontophoresis |
US5158537A (en) * | 1990-10-29 | 1992-10-27 | Alza Corporation | Iontophoretic delivery device and method of hydrating same |
US5224927A (en) * | 1990-11-01 | 1993-07-06 | Robert Tapper | Iontophoretic treatment system |
US6238381B1 (en) * | 1990-11-01 | 2001-05-29 | Robert Tapper | Iontophoretic treatment system |
US5464387A (en) * | 1991-07-24 | 1995-11-07 | Alza Corporation | Transdermal delivery device |
US5310404A (en) * | 1992-06-01 | 1994-05-10 | Alza Corporation | Iontophoretic delivery device and method of hydrating same |
AU4399193A (en) * | 1992-06-02 | 1993-12-30 | Alza Corporation | Iontophoretic drug delivery apparatus |
ES2112552T3 (en) * | 1992-06-02 | 1998-04-01 | Alza Corp | DEVICE FOR THE ADMINISTRATION OF A MEDICINAL PRODUCT BY ELECTRIC TRANSPORT. |
US5458569A (en) * | 1993-06-08 | 1995-10-17 | Becton Dickinson And Company | Wearable iontophoresis system |
US5533971A (en) * | 1993-09-03 | 1996-07-09 | Alza Corporation | Reduction of skin irritation during electrotransport |
US5540669A (en) * | 1993-09-30 | 1996-07-30 | Becton, Dickinson And Company | Iontophoretic drug delivery system and method for using same |
CA2172991A1 (en) * | 1993-09-30 | 1995-04-06 | Burton H. Sage, Jr. | Iontophoretic drug delivery system and method |
US6377847B1 (en) * | 1993-09-30 | 2002-04-23 | Vyteris, Inc. | Iontophoretic drug delivery device and reservoir and method of making same |
US5645526A (en) * | 1994-09-30 | 1997-07-08 | Becton Dickinson And Company | Apparatus and method for ensuring compatibility of a reusable iontophoretic controller with an iontophoretic patch |
US5697896A (en) * | 1994-12-08 | 1997-12-16 | Alza Corporation | Electrotransport delivery device |
US6425892B2 (en) * | 1995-06-05 | 2002-07-30 | Alza Corporation | Device for transdermal electrotransport delivery of fentanyl and sufentanil |
CN1147329C (en) * | 1995-06-05 | 2004-04-28 | 阿尔萨公司 | Device for trandermal electrotransport delivery of fentanyl and sufentanil |
US6216033B1 (en) * | 1996-05-22 | 2001-04-10 | Alza Corporation | Device for transdermal electrotransport delivery of fentanyl and sufentanil |
US7572252B1 (en) * | 1995-06-07 | 2009-08-11 | Alza Corporation | Electrotransport agent delivery method and apparatus |
US5954685A (en) * | 1996-05-24 | 1999-09-21 | Cygnus, Inc. | Electrochemical sensor with dual purpose electrode |
US6086572A (en) * | 1996-05-31 | 2000-07-11 | Alza Corporation | Electrotransport device and method of setting output |
US5738647A (en) * | 1996-09-27 | 1998-04-14 | Becton Dickinson And Company | User activated iontophoretic device and method for activating same |
US6047208A (en) * | 1997-08-27 | 2000-04-04 | Becton, Dickinson And Company | Iontophoretic controller |
US6059736A (en) * | 1998-02-24 | 2000-05-09 | Tapper; Robert | Sensor controlled analysis and therapeutic delivery system |
US6554798B1 (en) * | 1998-08-18 | 2003-04-29 | Medtronic Minimed, Inc. | External infusion device with remote programming, bolus estimator and/or vibration alarm capabilities |
US6949081B1 (en) * | 1998-08-26 | 2005-09-27 | Non-Invasive Technology, Inc. | Sensing and interactive drug delivery |
EP1115454B1 (en) | 1998-08-31 | 2006-10-25 | Travanti Pharma Inc | Controlled dosage drug delivery system |
US6597946B2 (en) * | 1998-11-09 | 2003-07-22 | Transpharma Ltd. | Electronic card for transdermal drug delivery and analyte extraction |
US6611706B2 (en) * | 1998-11-09 | 2003-08-26 | Transpharma Ltd. | Monopolar and bipolar current application for transdermal drug delivery and analyte extraction |
US6148232A (en) * | 1998-11-09 | 2000-11-14 | Elecsys Ltd. | Transdermal drug delivery and analyte extraction |
US6477410B1 (en) * | 2000-05-31 | 2002-11-05 | Biophoretic Therapeutic Systems, Llc | Electrokinetic delivery of medicaments |
US7127285B2 (en) * | 1999-03-12 | 2006-10-24 | Transport Pharmaceuticals Inc. | Systems and methods for electrokinetic delivery of a substance |
EP1171195B1 (en) * | 1999-04-16 | 2005-03-16 | Johnson & Johnson Consumer Companies, Inc. | Electrotransport delivery system comprising internal sensors |
US6421561B1 (en) | 1999-12-30 | 2002-07-16 | Birch Point Medical, Inc. | Rate adjustable drug delivery system |
ATE342959T1 (en) * | 2000-07-14 | 2006-11-15 | Transform Pharmaceuticals Inc | SYSTEM AND METHOD FOR OPTIMIZING TISSUE BARRIER TRANSFER OF COMPOUNDS |
US6653014B2 (en) * | 2001-05-30 | 2003-11-25 | Birch Point Medical, Inc. | Power sources for iontophoretic drug delivery systems |
US7047069B2 (en) * | 2002-02-04 | 2006-05-16 | Ceramatec, Inc. | Iontophoretic fluid delivery device |
WO2003077970A2 (en) * | 2002-03-11 | 2003-09-25 | Altea Therapeutics Corporation | Transdermal integrated actuator device, methods of making and using same |
US6801804B2 (en) * | 2002-05-03 | 2004-10-05 | Aciont, Inc. | Device and method for monitoring and controlling electrical resistance at a tissue site undergoing iontophoresis |
US7371229B2 (en) * | 2003-01-28 | 2008-05-13 | Felix Theeuwes | Dual electrode advanced electrochemical delivery system |
US6745071B1 (en) * | 2003-02-21 | 2004-06-01 | Birch Point Medical, Inc. | Iontophoretic drug delivery system |
-
2005
- 2005-04-22 US US11/112,196 patent/US7856263B2/en not_active Expired - Fee Related
-
2006
- 2006-03-24 ES ES06748647.2T patent/ES2529454T3/en active Active
- 2006-03-24 CN CN2006800217869A patent/CN101203266B/en not_active Expired - Fee Related
- 2006-03-24 CA CA2608471A patent/CA2608471C/en not_active Expired - Fee Related
- 2006-03-24 EP EP06748647.2A patent/EP1877134B1/en not_active Not-in-force
- 2006-03-24 KR KR1020077026840A patent/KR100994631B1/en not_active IP Right Cessation
- 2006-03-24 WO PCT/US2006/010781 patent/WO2006115660A2/en active Application Filing
- 2006-03-24 AU AU2006240432A patent/AU2006240432B2/en not_active Ceased
-
2008
- 2008-12-05 HK HK08113266.2A patent/HK1120451A1/en not_active IP Right Cessation
-
2010
- 2010-11-29 US US12/955,043 patent/US8463373B2/en not_active Expired - Fee Related
-
2013
- 2013-05-13 US US13/893,039 patent/US9764130B2/en not_active Expired - Fee Related
Non-Patent Citations (1)
Title |
---|
See references of EP1877134A4 * |
Also Published As
Publication number | Publication date |
---|---|
US7856263B2 (en) | 2010-12-21 |
WO2006115660A3 (en) | 2007-11-15 |
CN101203266A (en) | 2008-06-18 |
EP1877134B1 (en) | 2014-12-03 |
US20060253061A1 (en) | 2006-11-09 |
US8463373B2 (en) | 2013-06-11 |
KR20080009723A (en) | 2008-01-29 |
KR100994631B1 (en) | 2010-11-15 |
AU2006240432A1 (en) | 2006-11-02 |
EP1877134A2 (en) | 2008-01-16 |
US20110087154A1 (en) | 2011-04-14 |
US20130245537A1 (en) | 2013-09-19 |
CA2608471C (en) | 2010-06-08 |
CN101203266B (en) | 2012-04-04 |
AU2006240432B2 (en) | 2010-08-19 |
CA2608471A1 (en) | 2006-11-02 |
HK1120451A1 (en) | 2009-04-03 |
US9764130B2 (en) | 2017-09-19 |
EP1877134A4 (en) | 2012-12-12 |
ES2529454T3 (en) | 2015-02-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2608471C (en) | Transdermal systems for the delivery of therapeutic agents including granisetron using iontophoresis | |
KR100376723B1 (en) | Electric transport transmission device | |
KR100482229B1 (en) | Electrotransport Agent Delivery Method and Apparatus | |
US7660627B2 (en) | Electrotransport delivery device having improved safety and reduced abuse potential | |
JP3181289B2 (en) | Two-stage iontophoretic drug administration system | |
US9956403B2 (en) | Active transdermal medicament patch and circuit board for same | |
CA2214564C (en) | Display for an electrotransport delivery device | |
JPH06506616A (en) | Device for reducing stimulation during iontophoresis drug administration | |
IE83316B1 (en) | Device for reducing sensation during iontophoretic drug delivery | |
WO2001036039A2 (en) | Iontophoretic transdermal delivery of peptides | |
EP0783345A1 (en) | Iontophoretic drug delivery system, including disposable patch and reusable, removable controller | |
WO1996010441A9 (en) | Iontophoretic drug delivery system, including disposable patch and reusable, removable controller |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200680021786.9 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006240432 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020077026840 Country of ref document: KR Ref document number: 2006748647 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2608471 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: RU |
|
ENP | Entry into the national phase |
Ref document number: 2006240432 Country of ref document: AU Date of ref document: 20060324 Kind code of ref document: A |